CPRX vs. BMRN

In the year-to-date period, CPRX achieves a 11.12% return, which is significantly higher than BMRN's -4.55% return. Over the past 10 years, CPRX has outperformed BMRN with an annualized return of 21.40%, while BMRN has yielded a comparatively lower -6.06% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and BioMarin Pharmaceutical Inc. (BMRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current CPRX Sharpe Ratio is 1.29, which is higher than the BMRN Sharpe Ratio of -0.83. The chart below compares the historical Sharpe Ratios of CPRX and BMRN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither CPRX nor BMRN has paid dividends to shareholders.

The maximum CPRX drawdown since its inception was -94.25%, roughly equal to the maximum BMRN drawdown of -90.58%. Use the drawdown chart below to compare losses from any high point for CPRX and BMRN. For additional features, visit the drawdowns tool.

The current volatility for Catalyst Pharmaceuticals, Inc. (CPRX) is 14.57%, while BioMarin Pharmaceutical Inc. (BMRN) has a volatility of 17.84%. This indicates that CPRX experiences smaller price fluctuations and is considered to be less risky than BMRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Catalyst Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.